09.29.11
Tony Kingsley has been promoted to executive vice president of Global Commercial Operations at Biogen Idec, effective November 7th. Mr. Kingsley will oversee development and execution of Biogen Idec’s global commercial business strategies, reporting directly to chief executive officer George A. Scangos, Ph.D. Dr. Francesco Granata, who has headed global commercial operations since early 2010, is leaving to pursue other opportunities but will remain through the end of February to help ensure a smooth transition.
Since January 2010, Mr. Kingsley has served as Biogen’s senior vice president of U.S. Commercial Operations, responsible for all U.S. commercial functions, including marketing, sales, market access, patient services, training and sales operations. Prior to joining the company, he was senior vice president and general manager, Gynecological Surgical Products at Hologic, Inc., and division president, Diagnostic Products, at Cytyc Corp.
“Tony has demonstrated exceptional leadership since joining Biogen Idec, including playing a key role in strengthening U.S. AVONEX sales, growing TYSABRI sales and advancing our risk-stratification strategy for TYSABRI,” said Dr. Scangos. “Tony exemplifies the high-impact talent that we value at Biogen Idec. With his combination of strategic insight and operational expertise, I am confident he is the right person to build on the positive momentum in our global commercial business and prepare the organization for the potential launch of multiple products in the next several years.”
Since January 2010, Mr. Kingsley has served as Biogen’s senior vice president of U.S. Commercial Operations, responsible for all U.S. commercial functions, including marketing, sales, market access, patient services, training and sales operations. Prior to joining the company, he was senior vice president and general manager, Gynecological Surgical Products at Hologic, Inc., and division president, Diagnostic Products, at Cytyc Corp.
“Tony has demonstrated exceptional leadership since joining Biogen Idec, including playing a key role in strengthening U.S. AVONEX sales, growing TYSABRI sales and advancing our risk-stratification strategy for TYSABRI,” said Dr. Scangos. “Tony exemplifies the high-impact talent that we value at Biogen Idec. With his combination of strategic insight and operational expertise, I am confident he is the right person to build on the positive momentum in our global commercial business and prepare the organization for the potential launch of multiple products in the next several years.”